Precision medicine uses prostate-specific membrane antigen (PSMA)-directed radioligand imaging (RLI) to identify patients for treatment with RLT, which binds radioactive molecules directly to the targeted cancer cells (8, 9). This evidence concerns the gene FOLH1 and cancer.